USANA Health Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
USANA Health Sciences, Inc. (USNA) filed this Current Report on Form 8-K on January 12, 2026. The filing announces preliminary net sales for the fiscal year ended January 3, 2026, and provides initial net sales guidance for the fiscal year ending January 2, 2027.
Key Financial Metrics
The filing text references preliminary net sales for the full fiscal year 2026 and guidance for fiscal year 2027 but does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the body of this report. These figures are contained in the attached press release (Exhibit 99.1), which is not included in the provided text.
Material Changes
No specific material changes versus prior periods are quantified in this filing text. The report serves as a notification that preliminary results and guidance have been issued.
Guidance, Outlook, and Risks
- Guidance: The Company issued initial net sales guidance for the fiscal year ending January 2, 2027.
- Outlook: Preliminary net sales for the fiscal year ended January 3, 2026, were announced.
- Regulatory Note: The information in this report, including the press release, is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It shall not be incorporated by reference into other registration statements.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the specific preliminary net sales figures for fiscal year 2026.
- Verify the specific net sales guidance range or target for fiscal year 2027 in the attached press release.
- Confirm if the preliminary results include any adjustments or unusual items not detailed in this summary.
- Check subsequent filings for the full audited financial statements for the period ended January 3, 2026.